DIRECT MEDICAL COST ASSOCIATED WITH THE DIAGNOSIS AND TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS-B IN THREE LARGE METROPOLITAN CITIES IN INDIA – A PILOT STUDY

Author(s)

Marfatia S1, Gupta K2, Mukherjee A3, Mattoo V3
1pharmEDGE, Syosset, NY, USA, 2Bristol-Myers Squibb, Plainsboro, NJ, USA, 3Bristol-Myers Squibb, Mumbai, India

OBJECTIVES: To estimate the annual average per patient cost for diagnosing and treating chronic hepatitis B (CHB) and its complications in three large metropolitan cities in India. METHODS: Health resources consumed during the diagnosis and treatment of CHB and its complications were estimated by administering a structured survey to a total of 30 participating physicians from 3 cities (8 hepatologist/gastroenterologist and 2 oncologist treating hepatocellular carcinoma patients per city). Equal number of physicians from private and central government health scheme hospitals (CGHS) participated in the survey. Cost for laboratory tests, imaging, procedures, hospital admissions, physician visits, and drugs received on an inpatient and outpatient basis were estimated using rates provided by private setting centres and CGHS approved rates in the 3 cities. Mean, median, standard deviation, and frequency were used to analyze data. RESULTS: Total annual average cost for treating CHB, compensated cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma (HCC) were INR 79,768 (USD 1,269), INR 53,223 (USD 846), INR 3,99,316 (USD 6,355), and INR 5,069,12 (USD 8,067) in a private hospital and INR 49,796 (USD 792), INR 33,976 (USD 538), INR 2,73,564 (USD 4,353), and INR 358,071 (USD 5,698) in a CGHS hospital, respectively. The added inpatient cost of undergoing liver transplant for eligible HCC patients was on an average INR 25,00,000 (USD 39,783). CONCLUSIONS: Findings from our study provide an initial understanding of the magnitude of direct medical cost burden that CHB and its complications impose on patients in India. The results highlight the increasing health-care cost related to disease progression which can be potentially reduced by effective prevention strategies, early treatment, and patient education to improve adherence to treatment. Future efforts should focus on conducting large observational studies using patient level data and develop models to support uptake of cost-effective strategies to manage the burden of CHB in India.

Conference/Value in Health Info

2015-11, ISPOR Europe 2015, Milan, Italy

Value in Health, Vol. 18, No. 7 (November 2015)

Code

PIN35

Topic

Economic Evaluation

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies

Disease

Infectious Disease (non-vaccine)

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×